mitoxantrone has been researched along with Rhabdomyosarcoma in 6 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Rhabdomyosarcoma: A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two children, who had received chemotherapy with doxorubicin and cisplatin for disseminated chondrosarcoma and recurrent rhabdomyosarcoma, developed congestive heart failure following treatment with mitoxantrone (DHAD); the total doses of DHAD were 128 and 90 mg/m2, respectively." | 7.66 | Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin. ( Crom, DB; Miliauskas, J; Pratt, CB; Sanyal, SK; Sohlberg, K; Wallenberg, J, 1983) |
| "From June 1997 to November 1999, 28 SRCT patients (median age, 26 years; 14 peripheral primitive neuroectodermal tumors [pPNETs], seven rhabdomyosarcomas [RMSs], and seven desmoplastic small round-cell tumors [DSRCTs]) received induction chemotherapy with ifosfamide, epirubicin, and vincristine followed by HD-CT." | 5.10 | High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. ( Alloisio, M; Balzarotti, M; Bertuzzi, A; Castagna, L; Compasso, S; Nozza, A; Quagliuolo, V; Santoro, A; Siracusano, L; Soto Parra, H, 2002) |
| "Two children, who had received chemotherapy with doxorubicin and cisplatin for disseminated chondrosarcoma and recurrent rhabdomyosarcoma, developed congestive heart failure following treatment with mitoxantrone (DHAD); the total doses of DHAD were 128 and 90 mg/m2, respectively." | 3.66 | Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin. ( Crom, DB; Miliauskas, J; Pratt, CB; Sanyal, SK; Sohlberg, K; Wallenberg, J, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kishimoto, TE | 1 |
| Yashima, S | 1 |
| Nakahira, R | 1 |
| Onozawa, E | 1 |
| Azakami, D | 1 |
| Ujike, M | 1 |
| Ochiai, K | 1 |
| Ishiwata, T | 1 |
| Takahashi, K | 1 |
| Michishita, M | 1 |
| Krukemeyer, MG | 2 |
| Krenn, V | 2 |
| Jakobs, M | 2 |
| Wagner, W | 2 |
| Pratt, CB | 1 |
| Crom, DB | 1 |
| Wallenberg, J | 1 |
| Sanyal, SK | 1 |
| Miliauskas, J | 1 |
| Sohlberg, K | 1 |
| van Bree, C | 1 |
| Schopman, EM | 1 |
| Bakker, PJ | 1 |
| Kipp, JB | 1 |
| Barendsen, GW | 1 |
| Bertuzzi, A | 1 |
| Castagna, L | 1 |
| Nozza, A | 1 |
| Quagliuolo, V | 1 |
| Siracusano, L | 1 |
| Balzarotti, M | 1 |
| Compasso, S | 1 |
| Alloisio, M | 1 |
| Soto Parra, H | 1 |
| Santoro, A | 1 |
1 trial available for mitoxantrone and Rhabdomyosarcoma
| Article | Year |
|---|---|
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophos | 2002 |
5 other studies available for mitoxantrone and Rhabdomyosarcoma
| Article | Year |
|---|---|
Identification of tumor-initiating cells derived from two canine rhabdomyosarcoma cell lines.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dog Diseases; Dogs; Doxorubicin; Drug Resistance, | 2017 |
Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Delivery Systems; Ferric Compounds; Liv | 2012 |
Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 tesla extracorporeal magnets - sarcoma treatment in progress.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dextrans; Dose-Response Relationship, Drug; Drug D | 2012 |
Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin.
Topics: Anthraquinones; Child; Child, Preschool; Chondrosarcoma; Cisplatin; Doxorubicin; Female; Heart; Hear | 1983 |
Local hyperthermic treatment does not enhance mitoxantrone effectiveness for responses of a rat solid tumour regrowing after irradiation.
Topics: Animals; Antineoplastic Agents; Cell Division; Combined Modality Therapy; Female; Hyperthermia, Indu | 1996 |